Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY 64 Net Margin % is 34.62% as of Dec. 2025. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, HBM Holdings ranks better than 96.18% on this metric.
Net margin is calculated as Net Income divided by its Revenue. HBM Holdings's Net Income for the
six
months ended in Dec. 2025 was €16.8 Mil. HBM Holdings's Revenue for the
six
months ended in Dec. 2025 was €48.4 Mil. Therefore, HBM Holdings's net margin for the quarter that ended in Dec. 2025 was 34.62%.
The historical rank and industry rank for HBM Holdings's Net Margin % or its related term are showing as below:
FRA:6XY'
s Net Margin % Range Over the Past 10 Years
Min: -3198.18 Med: -791.18 Max: 57.89
Current: 57.89
FRA:6XY's Net Margin % is ranked better than 96.18% of 943
companies
in the Biotechnology industry
Industry Median: -89.56
vs FRA:6XY: 57.89
HBM Holdings (FRA:6XY) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
HBM Holdings Net Margin % Related Terms
HBM Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for HBM Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, HBM Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a Net Margin % of 34.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on HBM Holdings and its competitors. According to the industry distribution chart, HBM Holdings ranks #36 out of 943 companies in the Biotechnology industry, placing it in the top 3.8%.
Is HBM Holdings' Net Margin % too high?
HBM Holdings' current Net Margin % is 34.62%. Based on the distribution chart, HBM Holdings ranks #36 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #36 out of 943 companies for Net Margin %. This places HBM Holdings in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on HBM Holdings and its competitors. HBM Holdings's current Net Margin % is 34.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current Net Margin % is 34.62%. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current Net Margin % is 34.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
Net Margin %: 34.62%
GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
